LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Ventyx Biosciences Inc

Closed

2.45 8.89

Overview

Share price change

24h

Current

Min

2.22

Max

2.46

Key metrics

By Trading Economics

Income

1.9M

-27M

EPS

-0.39

Employees

81

EBITDA

2.4M

-30M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+779.4% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

42M

145M

Previous open

-6.44

Previous close

2.45

Ventyx Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Sept 2024, 12:43 UTC

Major Market Movers

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Peer Comparison

Price change

Ventyx Biosciences Inc Forecast

Price Target

By TipRanks

779.4% upside

12 Months Forecast

Average 17.5 USD  779.4%

High 21 USD

Low 14 USD

Based on 5 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.